IPO
Homology Medicines has raised $144 million in an initial public offering of stock.
Akebia Therapeutics, a kidney disease company, announced plans to offer and sell about $85 million of its common stock in an underwritten public offering.
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
In its IPO announcement last week Unum revealed early data from its Phase I non-Hodgkin lymphoma therapy that included toxicity concerns at higher dosing levels.
The Branford, CT-based company was founded in 2017 and plans to list on the Nasdaq under the symbol BTAI.
The company plans to raise $30 million by offering 4.3 million shares at a price range of $6 to $8.
The surprising disclosure was outlined in a November 2017 letter from the FDA.
The company’s Luye Medical Group unit plans to evaluate proposals from investment banks as soon as next month, according to the people.
The company believes its ultrasensitive immunoassay technology is well-suited to pharma research.
resTORbio is developing novel therapies to improve immune function in the elderly.
PRESS RELEASES